Purpose Novel multidrug resistance (mdr) modulators have been proved as inhibitors of P-
glycoprotein (P-gp). We first investigated the in vitro effects of selected compounds in human …

Overexpression of P-glycoprotein (P-gp) by tumours results in multidrug resistance (MDR) to
structurally and functionally unrelated chemotherapeutic drugs. Combined therapy with …

Expression of the multidrug resistance (MDR) phenotype is responsible for chemotherapy
failure in numerous cancers. Overexpression of mdr1 gene-encoded permeability …

Abstract P-glycoprotein (P-gp) mediated multidrug resistance (MDR) is one of the main
obstacles in tumour chemotherapy. A promising approach to reverse MDR is the combined …

Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy. One of
the main underlying mechanisms of this resistance is the over-expression of P-glycoprotein …

The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells causes multidrug
resistance (MDR). This protein acts as an energy-dependent drug efflux pump reducing the …

In recent years, there has been an increased understanding of P-glycoprotein (P-GP)-
mediated pharmacokinetic interactions. In addition, its role in modifying the bioavailability of …

Multidrug resistance, MDR is a major obstacle for cancer chemotherapy. MDR can be
reversed by drugs that vary in their chemical structure and main biological activity. Many …

The overexpression of permeability-glycoprotein (P-gp) and other drug transporters (ATP-
binding cassette) confers a multidrug resistance (MDR) phenotype on cells in various …

The application of most agents with the capacity to reverse multidrug resistance (MDR) via
modulation of the multidrug transporter P-glycoprotein (Pgp) was shown to be associated …